Important Oncology Titles from Pergamon Press

THE BASIC SCIENCE OF ONCOLOGY
Edited by Ian F. Tannock, M.D., Ph.D. & Richard P. Hill, Ph.D.
The Ontario Cancer Institute and
The University of Toronto,
Toronto, Ontario, Canada

This text covers all aspects of basic science related to cancer causation, biology and treatment. It is designed as a reference for those involved in cancer treatment and for students with an interest in cancer, such as residents in clinical and radiation oncology and pre- and post-doctoral trainees and workers in cancer research. Important concepts are evaluated critically, with liberal use of examples and illustrations.

CONTENTS
INTRODUCTION: Cancer as a Cellular Disease • SECTION I: Cancer Causation • SECTION II: Cancer Biology • SECTION III: Biology Underlying Cancer Treatment

0 08 032389 8 hardcover $87.50
0 08 032388 X softcover $37.50

RODENT TUMOR MODELS IN EXPERIMENTAL CANCER THERAPY
Edited by Robert F. Kallman, Ph.D.
Stanford University Medical Center
Stanford, CA, USA

This volume compiles and integrates findings of many of the leaders in cancer research. The major objective is to create a set of guiding principles for experiments with animal tumors for researchers in oncology, radiation oncology, pharmacology, and immunology.

April 1987 0 08 033145 9
430 pp. approx. hardcover $55.00

ONCOGENIC VIRUSES, Third Edition
by Ludwik Gross, M.D., F.A.C.P.
Veterans Administration Medical Center
Bronx, NY, USA

ONCOGENIC VIRUSES is an essential reference for graduate students and researchers in cancer, and medical libraries.

"A valuable addition to the libraries of scientists working in the field of medicine and medical research."
—Journal of the American Medical Association

1983 0 08 026830 7 1203 pp. (2-volume set)
hardcover $180.00

MOUNT VERNON HOSPITAL
FAIRFAX HOSPITAL SYSTEM

ONCOLOGY FELLOWSHIPS

Positions are available to physicians who are licensed to practice medicine in the United States and have at least two years of training in medicine or surgery.

The oncology training offers a one year fellowship beginning July 1, 1988 and July 1, 1989. The program consists of primary clinical responsibility of both in-patients and out-patients undergoing treatment with various biologic response modifiers and chemotherapeutic agents.

Continuity of patient care, principles of patient management, and design and conduct of clinical trials are stressed. Seminars and conferences on biostatistics, immunology, cell biology, molecular biology, clinical pharmacology, and diagnostic pathology and radiology are given regularly.

The annual salary is $45,000.00, including medical and dental insurance, life insurance, vacation, and sick leave. In addition, moving and travel expenses are available.

For further information please contact:
Medical Director, Clinical Cancer Institute
Mount Vernon Hospital
2501 Parker's Lane
Alexandria, VA 22306
(703) 664-7102

ANNOUNCEMENT


Abstracts of proffered papers on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer are invited. Abstract deadline is July 1, 1988.

Sponsored by The Cancer Therapy and Research Foundation of South Texas and the American Cancer Society, Texas Division, Inc. in conjunction with The University of Texas Health Science Center at San Antonio.

Abstract forms are obtained from Terri Coleman, RN, 4450 Medical Drive, San Antonio, Texas 78229.
The recipients of the awards to be presented at the 1988 annual meeting of the American Association for Cancer Research are featured on the cover. The meeting will be held in New Orleans from May 24 to 28. Each awardee will deliver a lecture following the presentation.

The 28th G. H. A. Clowes awardee is Isaiah J. Fidler. This award, given for “outstanding research accomplished in some recent period," was established by the Eli Lilly company and named for an early research director of the firm and one of the prominent founding members of the AACR. Fidler is a leading scientist in the biology and therapy of metastases and the role of macrophages in metastatic growth and regression. He innovated the use of liposomes to deliver soluble activating agents to macrophages. This work is also being applied to the therapy of viral and fungal diseases.

The 12th Rosenthal Foundation award, “to recognize research which has made or gives the promise of soon making a notable contribution to improved clinical care in the field of cancer,” is being given to Frederick P. Li. Li’s unique clinical and epidemiological studies have identified persons at high risk for cancer and elucidated late effects of therapy. His multidisciplinary research uses results from laboratory, clinical, and epidemiological studies to elucidate genetics and carcinogenesis.

Norbert Brock will receive the 7th Cain Award, given by the Warner Lambert Company to honor “an individual or research team for outstanding preclinical research leading to the discovery of a significant new therapeutic agent for the improved care of cancer patients.” Brock is recognized for his work on the development of cyclophosphamide, an important agent used against many kinds of cancer. For over 30 years he has contributed to knowledge about the activation, reactivity, and selectivity of this and related compounds. The award commemorates Bruce F. Cain, a prominent researcher in the field of antitumor drug development.

The 9th Rhoads Memorial Award, established in memory of Cornelius P. Rhoads, founder and first director of the Sloan-Kettering Institute for Cancer Research, will be presented to Webster K. Cavenee. This award “recognizes an individual on the basis of meritorious achievement in cancer research.” Cavenee has made original contributions to the genetic basis of hereditary cancers. His work showing an association of a recessive mutation with the development of retinoblastoma has prompted the search for other recessive mutations in human cancer. Cavenee has also developed novel sophisticated techniques for molecular genetics research.

Pictured on the cover are, left to right, Cavenee, Brock, Li, and Fidler. Cavenee is Director of the Ludwig Institute in Montreal. Brock is in the Pharmacology Department of Asta Werke, A. G., of Bielefeld, West Germany. Li is Head of the Clinical Studies Section, Clinical Epidemiology Branch, National Cancer Institute; Associate Professor of Medicine, Harvard Medical School; and Lecturer of Epidemiology, Harvard School of Public Health. Fidler is Bob Smith Professor of Cell Biology, Chairman of the Department of Cell Biology, and Director of Interferon Research at the University of Texas System Cancer Center and M. D. Anderson Hospital and Tumor Institute.

Sidney Weinhouse